US Patent

US11439629 — Methods for the administration of certain VMAT2 inhibitors

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2037-10-10 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering valbenazine toosylate to patients who are poor metabolizers of CYP2D6.

USPTO Abstract

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate

Patent Metadata

Patent number
US11439629
Jurisdiction
US
Classification
Method of Use
Expires
2037-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.